Global Kinetics and uMotif announce technology partnership for Parkinson’s trials

Posted: 2016-12-16 in Press Releases

Download PDF

Media Release

16th December 2016

 

Global Kinetics and uMotif announce technology partnership for Parkinson’s trials

Global Kinetics Corporation and uMotif have announced a new partnership to offer a comprehensive, validated and simple to use data capture platform to advance the treatment and understanding of Parkinson’s disease.

Bringing together leading proprietary products, the combined Global Kinetics and uMotif Parkinson’s platform provides a unique means to measure and demonstrate the value of medications, devices and services in Parkinson’s disease, from clinical through to commercial phases of development.

The combined Parkinson’s platform is based on two leading clinically validated systems for clinical trials:

  • Global Kinetics’ Parkinson’s KinetiGraph™ (PKG™) system incorporating a wrist- worn device and cloud-based proprietary algorithms to objectively and continuously record movement symptoms including bradykinesia, dyskinesia, tremor and the relationships of these to medication timing, sleep and exercise.
  • uMotif’s elegant mobile and web platform for trial data capture allowing electronic capture of patient reported data including e-consent, patient reported outcomes (ePRO) and clinical outcomes assessments (eCOA), diaries and symptom tracking.

The Global Kinetics PKG™ system is now in use in in 200 specialist clinics across 17 countries. More than 13,000 PKG™ reports have been delivered to date, underpinning a vast pool of experience and data which is increasingly being leveraged by leading companies in Parkinson’s. Global Kinetics’ second generation Parkinson’s KinetiGraph™ (PKG™) system, which which has been designed to allow 365 day/24 hour use, recently received FDA clearance and will shortly be CE marked.

Since 2012, the uMotif platform has been at the forefont of patient-centred data capture in Parkinson’s Disease and 15 other clinical conditions. Working with the UK’s leading neurologists, uMotif is the only platform to be proven through a large-scale Randomised Controlled Trial in the NHS – the Smart PD trial – accepted for publication in Nature Parkinson’s Journal. uMotif’s ‘100 for Parkinson’s’ observational study is now the world’s largest Bring Your Own Device study, with over 4,200 participants in the UK and USA capturing millions of research data points, and validating the platform in a multi-national study.

Both companies are already working extensively with multinational and small pharmaceutical and device companies to support commercial product development in Parkinson’s and other indications. Recognising the increasing needs of commercial sponsors for streamlined and high quality trial data collection, including both objective and patient-reported measures, Global Kinetics and uMotif have successfully brought together their complementary technologies into a single platform for Parkinson’s trials.

Global Kinetics President and CEO Timothy Still said: “This exciting partnership with uMotif represents a significant strategic move for our company alongside our fast growing clinical product for routine management of Parkinson’s disease. Responding to the needs of commercial sponsors for high quality data and systems to support both traditional and innovative trial designs, we have developed an unparalleled integrated offer with uMotif. I am confident that this partnership will provide a useful tool for companies and researchers working to develop new therapies, disease modifying treatments and even a cure for Parkinson’s.”

Hellman, CEO of uMotif said: “The past few years have seen rapid growth in the use of the uMotif platform, chosen by major world-leading clients and partners to capture high quality patient-reported data for global research projects and trials. Global Kinetics are natural partners for uMotif, bringing a clinically validated, regulator approved system for objective measurement that complements our platform beautifully.”

The Global Kinetics and uMotif Parkinson’s platform is now available globally for all phases of Parkinson’s trials.

ENDS

 

For commercial sponsors interested in using the Global Kinetics and uMotif Parkinson’s platform please contact:
Michelle Goldsmith on +61 417 554 632 or at michelle.goldsmith@globalkineticscorp.com

For media enquiries please contact:
Nathan Clarke on +61 3 9993 0894 or at n.clarke@sixoclock.com.au

Follow updates from Global Kinetics Corporation via the company LinkedIn page:

https://www.linkedin.com/company/globalkineticscorp

About Global Kinetics Corporation

Global Kinetics is a commercial-stage digital health company revolutionising the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments. The company’s Parkinson’s KinetiGraph (PKG) is a patient- friendly, algorithm-based system that records body movements and other symptoms over the course of many days and creates data-driven reports that empower more personalized treatment and management decisions—with the goal of leading to a higher quality of life for patients. Global Kinetics continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure the efficacy of new and advanced therapies for the world’s most widespread movement disorder.

For more information, visit: www.globalkineticscorporation.com

About uMotif

uMotif is the leading next-generation digital platform to capture patient-generated health data for clinical research – experienced in 16 clinical conditions. uMotif captures high quality clinical research data (eCOA / ePRO) from patients, through digital tools they love to use. Our unrivalled design quality engages patients of all ages to track symptoms, outcomes, experience, medications and wearable- device data. Through our cloud-based, validated and secure system, we’re fast, flexible and cost- effective, helping modernise the global clinical trials data capture industry – with patients at the centre.

For more information, visit: https://www.umotif.com/